MedElevator
Войти в исследования Pan American League of Associations for Rheumatology: Recommendations for the Treatment of Oligoarticular Juvenile Idiopathic Arthritis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morel Zoilo, Espada Graciela, Eraso Ruth, Silva Clovis A, Gutiérrez-Suárez Raúl, Franco Lorena, Barzola María L, Cameto Caffa Juan A, Faugier-Fuentes Enrique, Zuccardi Pilar Guarnizo, Herrera Cristina N, Ibañez E Amparo, Jiménez Cruz Karen V, Jurado Rosario M, León Beatriz H, Rodrigues Fonseca Adriana, Tineo Rodríguez Carmen M, Arroyo Rivera Ivonne L, Ferrándiz Manuel A, Cuttica Rubén J, Talesnik Eduardo, Ringer Ariana, Ramírez Stieben Luis A, Brun Lucas R, Marín Zúcaro Nicolás M, Fernández-Ávila Daniel G, Brance María Lorena, Appenzeller Simone, Pan American League of Associations for Rheumatology (PANLAR)
Аннотация
METHODS: A panel of pediatric rheumatologists from Latin-America (LATAM) generated clinically meaningful questions related to the treatment of oligo-JIA patients, using Population, Intervention, Comparator, and Outcome (PICO) format. Following Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology, a team of methodologists conducted a systematic literature review, extracted, summarized intervention effect estimates, and graded the evidence quality. LATAM pediatric rheumatology experts' panel voted each PICO question, which required a minimum agreement of 70% among the voting members and developed recommendations.
RESULTS: Seven recommendations and 4 expert opinion were developed. Short-term course of NSAID and intra-articular corticosteroids was recommended as initial therapy in those with minimal disease activity with no risk factors for poor prognosis. The initiation of a nbDMARD was recommended in patients with high disease activity and risk factors for poor prognosis. For patients who achieve inactive disease state, treatment with DMARD should be maintained for a minimum of 12 months after remission. We proposed sulfasalazine or leflunomide in patients with methotrexate intolerance, or in the presence of contraindication or unavailability of bDMARD. For oligo-JIA patients with high disease activity or uveitis, anti-TNF agents are recommended as the first choice among bDMARD. Regular physical activity was also recommended for these patients.
CONCLUSIONS: The first PANLAR oligo-JIA treatment guidelines provide evidence-based guidance for health care providers, treating patients with oligo-JIA in LATAM.